These findings suggested that linsitinib treatment stabilized IGF-1R and Src proteins in low-pSrc-expressing NSCLC cells, ultimately leading to the enhanced reciprocal activation of IGF-1R and Src. The gene discussed is SRC; the disease is non-small cell lung carcinoma.